A
Abiologics
Innovative biologics leveraging AI and chemistry to create next-gen therapeutics for diverse diseases
About Abiologics
Abiologics is at the forefront of biotechnology, leveraging artificial intelligence and chemistry to develop a new class of supranatural and programmable biologics. These advanced therapeutics are designed to treat a wide range of diseases more effectively than traditional methods. The company primarily serves patients and healthcare providers, operating within the biopharmaceutical market. Abiologics employs a business model focused on research and development, creating proprietary biologics that are then licensed or sold to pharmaceutical companies. Revenue is generated through licensing agreements, partnerships, and direct sales of their innovative therapeutics. The company's multidisciplinary team combines expertise in machine learning and biology to systematically expand the toolkit for future medicines.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2020
- Headquarters
- Cambridge, United States
- Employees
- 24
- Open positions
- 1
- Dealroom signal
- 88.0/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Drug Development, Core AI, Biotech and Pharma, AI Drug Discovery, AI Applications, DT and LS, science-based
- Technology
- Artificial Intelligence
- Business model
- Manufacturing
- Client focus
- b2b
Latest news
Press, funding announcements and product moves mentioning Abiologics.
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| EARLY VCOther financing | Jul 2024 | $50M | $200M | Flagship Pioneering | ↗ |
Growth signals
Latest recorded traffic for Abiologics is 3K monthly website visits, up 76.5% over the last three months. Abiologics's team grew 41.2% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A1 investor entered at this stage
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Abiologics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Abiologics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.